Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial - The
Improved chemotherapy modeling with RAG-based immune deficient mice | PLOS ONE
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Methotrexate and cytarabine inhibit progression of human lymphoma in NOD/SCID mice carrying a mutant dihydrofolate reductase and cytidine deaminase fusion gene: Molecular Therapy
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Chemotherapy regimen. | Download Table
Acute Leukemias
Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv
Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
1930-R-MPV/high dose cytarabine overview | eviQ
Cytarabine (Cytarabine): Uses, Dosage, Side Effects, Interactions, Warning
![PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/094147101525dbcb98a9d514f1a305a20a3a7f7c/3-Table1-1.png "PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar")
PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar
Melphalan and Cytarabine as a Salvage Therapy in Children with Relapsed or Refractory Acute Leukemia
Chemotherapy dosing schedule. The schedule for ARA-C (200 mg/m 2 /d),... | Download Scientific Diagram
7+3 (daunorubicin) for AML | ChemoExperts
Structural insights into mutagenicity of anticancer nucleoside analog cytarabine during replication by DNA polymerase η | Scientific Reports
Genetic factors influencing cytarabine therapy | Pharmacogenomics
A Comparative Study of Two Different Doses of Cytarabine for Acute Myeloid Leukemia: A Phase III Trial of Cancer and Leukemia Group B - ScienceDirect
Fernand Bteich on Twitter: "13/ Typical induction regimen is 7+3. Total is 7 days with 3 days of overlap. 7 days of cytarabine infusion. 3 days of anthracycline infusion (daunorubicin or idarubicin).
OUTCOME OF STANDARD INDUCTION THERAPY WITH DAUNORUBICIN AND ARA-C (3+7) IN ACUTE MYELOID LEUKEMIA
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
Induction therapy of AML with ara-C plus daunorubicin versus ara-C plus gemtuzumab ozogamicin: a randomized phase II trial in elderly patients - ScienceDirect
Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis | Scientific Reports
